Forbes J M & CO LLP Nuvectis Pharma, Inc. Transaction History
Forbes J M & CO LLP
- $1.01 Billion
- Q4 2024
A detailed history of Forbes J M & CO LLP transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Forbes J M & CO LLP holds 59,000 shares of NVCT stock, worth $395,890. This represents 0.03% of its overall portfolio holdings.
Number of Shares
59,000
Previous 48,401
21.9%
Holding current value
$395,890
Previous $304,000
5.26%
% of portfolio
0.03%
Previous 0.03%
Shares
5 transactions
Others Institutions Holding NVCT
# of Institutions
32Shares Held
1.9MCall Options Held
0Put Options Held
0-
Ronit Capital LLP563KShares$3.77 Million5.37% of portfolio
-
Baldwin Brothers LLC356KShares$2.39 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA325KShares$2.18 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0125KShares$835,8710.0% of portfolio
-
Black Rock Inc. New York, NY83.4KShares$559,6940.0% of portfolio
About Nuvectis Pharma, Inc.
- Ticker NVCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,642,500
- Market Cap $98.3M
- Description
- Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...